PTS-500 Market Summary

Key Factors Driving PTS-500 Growth

1. Large unmet need in malignant pleural effusion: MPE is a frequent complication of advanced cancers, particularly lung, breast and other solid tumors, and causes substantial dyspnea and quality-of-life deterioration. Current management is largely palliative—thoracentesis, pleurodesis or indwelling pleural catheters—while recurrence remains common. This creates an opportunity for a therapy capable of directly treating the underlying malignant pleural process rather than repeatedly removing accumulated fluid. A 2025 peer-reviewed study described PTS as a small-molecule agent with demonstrated anticancer activity in preclinical and clinical studies and specifically investigated its use for malignant pleural effusions.

2. Direct local administration could provide a differentiated treatment approach: PTS-500 uses para-toluenesulfonamide, a small-molecule tumor-ablation agent intended for local treatment. Gongwin's development strategy centers on minimally invasive targeted tumor ablation, potentially allowing high local exposure while limiting systemic drug exposure. This is particularly relevant for MPE because the drug can potentially be administered directly into the pleural cavity, creating an opportunity to address malignant cells within the pleural space. The company's pipeline specifically lists PTS-500 for MPE.

3. Clinical evidence is beginning to support the MPE opportunity: In a 2025 ASCO publication, investigators evaluated intrapleural PTS for MPE and reported preclinical evidence supporting its antitumor activity. The peer-reviewed literature also notes that PTS has demonstrated anticancer activity in earlier preclinical and clinical studies. Although the evidence remains early and should not yet be interpreted as proof of clinical efficacy in MPE, these findings provide a rationale for advancing PTS-500 into later-stage development.

4. Progression toward larger clinical development can expand commercial potential: Gongwin's pipeline identifies PTS-500 specifically for malignant pleural effusion, while external clinical-development information places the program in Phase II development. Gongwin has also been building a U.S. development platform: in July 2025, the company announced an LOI for up to US$50 million of investment into its U.S. subsidiary, which will hold U.S. patents for PTS-500 along with PTS-302 and PTS-02. The company stated that the U.S. subsidiary would subsequently conduct clinical trials and pursue market deployment, potentially giving PTS-500 access to a much larger commercial market if development succeeds.

5. Potential expansion alongside the broader PTS platform: PTS-500 is one component of Gongwin's broader PTS platform. The company is simultaneously developing PTS-100 for hepatocellular carcinoma, PTS-302 for severe malignant airway obstruction and PTS-02 for adenoid cystic carcinoma. Positive clinical/regulatory experience with one PTS-based product could potentially reduce development and commercialization barriers for other formulations/indications and create opportunities for PTS-500 across additional cancer-related effusion settings.

PTS-500 Recent Developments

In July 2025, Gongwin disclosed that it had engaged a fundraising adviser to support a planned US subsidiary financing of up to USD 100 million.

A prospective fund reportedly submitted a letter of intent to invest up to USD 50 million, representing approximately half of the proposed Series A financing.

Gongwin proposed contributing US patent rights for PTS-302, PTS-02 and PTS-500 in exchange for approximately 75% of the US subsidiary, with the balance intended to be sold to external investors.

“PTS-500 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of PTS-500 for approved indication like Lung Cancer; as well as potential indication like Adenoid cystic carcinoma, Malignant pleural effusion, Liver cancer, and Solid tumours in the 7MM. A detailed picture of PTS-500’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the PTS-500 for approved and potential indications. The PTS-500 market report provides insights about PTS-500’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current PTS-500 performance, future market assessments inclusive of the PTS-500 market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of PTS-500 sales forecasts, along with factors driving its market.

PTS-500 Drug Summary

PTS-500 is an investigational anticancer therapy developed by Gongwin Biopharm for the treatment of malignant pleural effusion (MPE), a condition in which cancer-associated fluid accumulates in the pleural cavity and can cause breathlessness, chest discomfort, and impaired quality of life. The active pharmaceutical ingredient in PTS-500 is para-toluenesulfonamide (PTS), which is designed to selectively target and eliminate cancer cells within the pleural cavity while reducing the recurrence of pleural fluid. Unlike conventional chemical pleurodesis agents such as talc, which work primarily by inducing inflammation and adhesion between the pleural layers, PTS-500 is intended to reduce malignant cells and pleural effusion without deliberately causing pleural adhesion. The therapy is being developed as a locally administered treatment for MPE, with Gongwin reporting preliminary evidence of reduced fluid accumulation and disappearance of cancer cells from pleural fluid after treatment. PTS-500 is currently in clinical development, with the company preparing Phase II/III studies in multiple countries, including Taiwan and the United States. The report provides PTS-500’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the PTS-500 Market Report

The report provides insights into:

• A comprehensive product overview including the PTS-500 MoA, description, dosage and administration, research and development activities in approved indications like Lung Cancer; as well as potential indication like Adenoid cystic carcinoma, Malignant pleural effusion, Liver cancer, and Solid tumours.
• Elaborated details on PTS-500 regulatory milestones and other development activities have been provided in PTS-500 market report.
• The report also highlights PTS-500‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The PTS-500 market report also covers the patents information, generic entry and impact on cost cut.
• The PTS-500 market report contains current and forecasted PTS-500 sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The PTS-500 market report also features the SWOT analysis with analyst views for PTS-500 in approved and potential indications.

Methodology

The PTS-500 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PTS-500 Analytical Perspective by DelveInsight

• In-depth PTS-500 Market Assessment

This PTS-500 sales market forecast report provides a detailed market assessment of PTS-500 for approved indication like Lung Cancer; as well as potential indication like Adenoid cystic carcinoma, Malignant pleural effusion, Liver cancer, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted PTS-500 sales data uptil 2034.

• PTS-500 Clinical Assessment

The PTS-500 market report provides the clinical trials information of PTS-500 for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

PTS-500 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

PTS-500 Market Potential & Revenue Forecast

• Projected market size for the PTS-500 and its key indications
• Estimated PTS-500 sales potential (PTS-500 peak sales forecasts)
• PTS-500 Pricing strategies and reimbursement landscape

PTS-500 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• PTS-500 Market positioning compared to existing treatments
• PTS-500 Strengths & weaknesses relative to competitors

PTS-500 Regulatory & Commercial Milestones

• PTS-500 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

PTS-500 Clinical Differentiation

• PTS-500 Efficacy & safety advantages over existing drugs
• PTS-500 Unique selling points

PTS-500 Market Report Highlights

• In the coming years, the PTS-500 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The PTS-500 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PTS-500’s dominance.
• Other emerging products for Lung Cancer; as well as potential indication like Adenoid cystic carcinoma, Malignant pleural effusion, Liver cancer, and Solid tumours are expected to give tough market competition to PTS-500 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PTS-500 in approved and potential indications.
• Analyse PTS-500 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted PTS-500 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of PTS-500 in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of PTS-500? How strong is PTS-500’s clinical and commercial performance?
• What is PTS-500’s clinical trial status in each individual indications such as Lung Cancer; as well as potential indication like Adenoid cystic carcinoma, Malignant pleural effusion, Liver cancer, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PTS-500 Manufacturers?
• What are the key designations that have been granted to PTS-500 for approved and potential indications? How are they going to impact PTS-500’s penetration in various geographies?
• What is the current and forecasted PTS-500 market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of PTS-500 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to PTS-500 for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is PTS-500? What is the duration of therapy and what are the geographical variations in cost per patient?